643 related articles for article (PubMed ID: 12714955)
1. 99mTc-MIBI in the assessment of response to chemotherapy and detection of recurrences in bone and soft tissue tumours of the extremities.
Moustafa H; Riad R; Omar W; Zaher A; Ebied E
Q J Nucl Med; 2003 Mar; 47(1):51-7. PubMed ID: 12714955
[TBL] [Abstract][Full Text] [Related]
2. A single (99m)Tc-MIBI study to predict response to neoadjuvant treatment in sarcoma patiens.
Sohaib M; Wiqar MA; Ali MK; Hussain F; Umer-i-Farooq
Hell J Nucl Med; 2011; 14(2):140-5. PubMed ID: 21761016
[TBL] [Abstract][Full Text] [Related]
3. The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response.
Burak Z; Ersoy O; Moretti JL; Erinç R; Ozcan Z; Dirlik A; Sabah D; Basdemir G
Eur J Nucl Med; 2001 Sep; 28(9):1341-50. PubMed ID: 11585293
[TBL] [Abstract][Full Text] [Related]
4. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy.
Taki J; Sumiya H; Asada N; Ueda Y; Tsuchiya H; Tonami N
J Nucl Med; 1998 Jul; 39(7):1179-84. PubMed ID: 9669390
[TBL] [Abstract][Full Text] [Related]
5. Prediction of final tumor response to preoperative chemotherapy by Tc-99m MIBI imaging at the middle of chemotherapy in malignant bone and soft tissue tumors: comparison with Tl-201 imaging.
Taki J; Higuchi T; Sumiya H; Tsuchiya H; Minato H; Tomita K; Tonami N
J Orthop Res; 2008 Mar; 26(3):411-8. PubMed ID: 17960652
[TBL] [Abstract][Full Text] [Related]
6. Evaluating benign and malignant bone and soft-tissue lesions with technetium-99m-MIBI scintigraphy.
Taki J; Sumiya H; Tsuchiya H; Tomita K; Nonomura A; Tonami N
J Nucl Med; 1997 Apr; 38(4):501-6. PubMed ID: 9098190
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of Tc-99m-MIBI performed during middle course of preoperative chemotherapy in patients with malignant bone and soft-tissue tumors.
Wakabayashi H; Taki J; Inaki A; Sumiya H; Zen Y; Tsuchiya H; Kinuya S
Clin Nucl Med; 2012 Jan; 37(1):1-8. PubMed ID: 22157020
[TBL] [Abstract][Full Text] [Related]
8. Early prediction of histopathological tumor response to preoperative chemotherapy by Tc-99m MIBI imaging in bone and soft tissue sarcomas.
Taki J; Inaki A; Wakabayashi H; Sumiya H; Tsuchiya H; Zen Y; Kinuya S
Clin Nucl Med; 2010 Mar; 35(3):154-9. PubMed ID: 20173444
[TBL] [Abstract][Full Text] [Related]
9. Triple-phase contrast-enhanced MRI for the prediction of preoperative chemotherapeutic effect in patients with osteosarcoma: comparison with (99m)Tc-MIBI scintigraphy.
Wakabayashi H; Saito J; Taki J; Hashimoto N; Tsuchiya H; Gabata T; Kinuya S
Skeletal Radiol; 2016 Jan; 45(1):87-95. PubMed ID: 26385785
[TBL] [Abstract][Full Text] [Related]
10. Correlation of 99mTc-sestamibi uptake with blood-pool and osseous phase 99mTc-MDP uptake in malignant bone and soft-tissue tumours.
Ozcan Z; Burak Z; Erinç R; Dirlik A; Başdemir G; Sabah D; Ozkiliç H
Nucl Med Commun; 2001 Jun; 22(6):679-83. PubMed ID: 11403180
[TBL] [Abstract][Full Text] [Related]
11. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.
Burak Z; Moretti JL; Ersoy O; Sanli U; Kantar M; Tamgac F; Basdemir G
J Nucl Med; 2003 Sep; 44(9):1394-401. PubMed ID: 12960182
[TBL] [Abstract][Full Text] [Related]
12. [²⁰¹TI and (99m)Tc-MIBI scintigraphy in evaluation of neoadjuvant chemotherapy for osteosarcoma].
Huang ZK; Lou C; Shi GH
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Mar; 41(2):183-7, 191. PubMed ID: 22499516
[TBL] [Abstract][Full Text] [Related]
13. Technetium-99m-tetrofosmin scintigraphy in patients with metastatic soft tissue sarcoma.
Karanikas G; Köstler WJ; Becherer A; Wiesner K; Dudczak R; Krainer M; Kletter K
Oncol Rep; 2002; 9(5):1009-13. PubMed ID: 12168065
[TBL] [Abstract][Full Text] [Related]
14. The correlation of Tc-99m MIBI scintigraphy and histological response in determining the percentage of tumor necrosis in osteosarcoma after preoperative chemotherapy.
Punyaratabandhu T; Wittayawongsaruji S; Rajchadara S; Thanakit V; Charoenvareekul S; Khunkitti N; Songpatanasilp T
J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S53-62. PubMed ID: 16862675
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of bone and soft tissue lesion using 99mTc-MIBI: comparison with 201Tl and the relation to chemotherapeutic effect].
Sumiya H; Taki J; Tonami N; Asada N; Tsuchiya H; Tomita K
Kaku Igaku; 1997 Feb; 34(2):105-11. PubMed ID: 9095573
[TBL] [Abstract][Full Text] [Related]
16. Use of 99mTc-MIBI scintigraphy in the evaluation of the response to chemotherapy for osteosarcoma: comparison with 201Tl scintigraphy and angiography.
Miwa S; Shirai T; Taki J; Sumiya H; Nishida H; Hayashi K; Takeuchi A; Ooi A; Tsuchiya H
Int J Clin Oncol; 2011 Aug; 16(4):373-8. PubMed ID: 21331769
[TBL] [Abstract][Full Text] [Related]
17. Double-phase Tc-99m MIBI scintigraphy as a therapeutic predictor in patients with non-Hodgkin's lymphoma.
Song HC; Lee JJ; Bom HS; Chung IJ; Kim HJ; Park YK; Kim EE
Clin Nucl Med; 2003 Jun; 28(6):457-62. PubMed ID: 12911092
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
Sergieva SB; Timcheva KV; Hadjiolov ND
J BUON; 2006; 11(1):61-8. PubMed ID: 17318954
[TBL] [Abstract][Full Text] [Related]
19. Assessment of 99mTc-MIBI SPECT(/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study.
Kurata S; Ushijima K; Kawahara A; Kaida H; Kawano K; Hirose Y; Kage M; Kamura T; Ishibashi M; Abe T
Ann Nucl Med; 2015 Aug; 29(7):643-9. PubMed ID: 25921216
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma: predictive value of Tc-99m MIBI scintigraphy and MRI in its diagnosis and therapy.
Myslivecek M; Nekula J; Bacovsky J; Scudla V; Koranda P; Kaminek M
Nucl Med Rev Cent East Eur; 2008; 11(1):12-6. PubMed ID: 19173182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
